Transplant outcomes in acute leukemia. II

Seminars in Hematology
Rachael Hough, V Rocha

Abstract

Currently, it is possible to find a hematopoietic stem cell (HSC) donor for virtually all patients with acute leukemia who have an indication to receive an allogeneic hematopoietic stem cell transplant (HSCT) and lack a human leukocyte antigen (HLA)-identical sibling or a well-matched HLA unrelated donor (URD). According to the ethnicity of the patients and the donor registry, approximately 25% to 60% of patients will not find an 8/8 HLA-matched unrelated donor. Other alternative donors, such as HLA-mismatched related donor or unrelated donor umbilical cord blood (UCB), have emerged to solve the lack of a sibling or well-matched URD. In the haploidentical HSCT setting, new techniques of T-cell depletion, new approaches using combinations of immunosuppressive drugs or different conditioning regimens, and developments on immunotherapy have focused attention on this option. Therefore, any physician has to carefully evaluate, for each patient in need of an allograft, all of the possible alternatives in order to choose the best HSC donor, taking into account type of disease to be transplanted, urgency of transplantation, donor characteristics, and center experience. This review evaluates the current status of haploidentical HSCT in ...Continue Reading

References

Sep 26, 1985·The New England Journal of Medicine·P G BeattyR Storb
Jun 18, 2002·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Juliet N BarkerDaniel J Weisdorf
Oct 23, 2004·Best Practice & Research. Clinical Haematology·Franco LocatelliRita Maccario
Nov 6, 2004·Blood Cells, Molecules & Diseases·Peter LangDietrich Niethammer
Nov 27, 2004·The New England Journal of Medicine·Mary J LaughlinMary M Horowitz
Nov 27, 2004·The New England Journal of Medicine·Vanderson RochaUNKNOWN Eurocord-Netcord Registry
Mar 9, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Franco AversaMassimo F Martelli
Mar 23, 2005·Pathologie-biologie·Thomas KlingebielRupert Handgretinger
Apr 28, 2006·The New England Journal of Medicine·Edward A Copelan
Jul 19, 2006·British Journal of Haematology·David I MarksJacqueline M Cornish
Sep 8, 2006·The New England Journal of Medicine·Matthew J Ellis, Uptal D Patel
Apr 20, 2007·Annals of the New York Academy of Sciences·Rupert HandgretingerPeter Lang
May 22, 2007·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·P ComoliF Locatelli
Dec 18, 2007·Bone Marrow Transplantation·V Rocha, F Locatelli
Jul 22, 2008·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Alexander DewKoen van Besien
Nov 26, 2008·Bone Marrow Transplantation·P Lang, R Handgretinger

❮ Previous
Next ❯

Citations

Dec 22, 2012·Journal of Biomedicine & Biotechnology·Somayeh ShahrokhiMassoumeh Ebtekar
Apr 2, 2010·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·Paolo Rebulla
Sep 18, 2010·Blood·Bipin N Savani

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.